Bionomics Ltd (AX:BNO) announced on 9 July 2018 that it had completed treatment in its 193-patient Phase II clinical study of BNC210 for post-traumatic stress disorder (PTSD). The RESTORE clinical study completed the treatment phase on time and the company stated that it intends to provide topline data by the end of calendar Q318.
PTSD Phase II complete
The RESTORE trial enrolled 193 patients at 25 clinical sites in the US and Australia. Patients were evaluated using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) as the primary endpoint. CAPS-5 is the approvable endpoint for PTSD, so results from the study should be highly predictive. The study is also examining anxiety and depression endpoints, which could provide insight into other avenues of treatment for the drug.
To read the entire report Please click on the pdf File Below:
Which stock should you buy in your very next trade?
With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Unsure where to invest next? Get access to our proven portfolios and discover high-potential opportunities.
In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record.
With portfolios tailored for Dow stocks, S&P stocks, Tech stocks, and Mid Cap stocks, you can explore various wealth-building strategies.